30-year-old female affected by skin symptoms and severe abdominal pain
Anne
51-year-old female struggling with ongoing gastrointestinal issues, skin symptoms and fatigue
John
60-year-old male burdened by cognitive symptoms, bone pain and fatigue
Please note that the patient quotes are illustrative and do not represent actual patient statements.
Emily
30-year-old female affected by skin symptoms and severe abdominal pain
Fast fact
In PRISM, the largest European HCP/patient survey of SM burden to date, 43% of ISM patients reported an impact on work despite current care2
Patient history:
“For the last five years, I’ve been dealing with on-and-off rashes, mostly on my body and limbs, along with flushing, itching and spots.”
Recently, Emily’s symptoms escalated, including severe abdominal pain and episodes of dizziness, especially after meals
H1 antihistamines were initiated, which provided relief but were not enough to resolve her episodes of flushing, itching, spots and abdominal pain
Triggers:
Cheese
Heat
Alcohol
Precautionary measures:
Carrying epinephrine as emergency medication
Emily’s allergist suspected a mast cell disorder based on elevated serum tryptase and her symptoms. A haematologist confirmed a diagnosis of indolent systemic mastocytosis with a positive KIT D816V mutation, and the presence of <10% mast cell infiltration and positive CD117 and CD25 on bone marrow biopsy, with ongoing management directed by her allergist
Burden of ISM:
Living with ISM means Emily has to constantly juggle her career and her health. Despite carefully planning her meals and activities to avoid triggers, sudden symptoms often cause her to miss work.
“After all these years, I can’t usually tell when my symptoms are about to hit. Even though I have talked to my colleagues and students about my condition, the constant worry about an unexpected flare-up leaves me feeling incredibly anxious and uncomfortable…”
Treatment with AYVAKYT:
Emily begins taking AYVAKYT 25 mg orally, once daily in addition to her other medications (H1 antihistamines)1
At a follow-up appointment at 24 weeks, she reports that she is tolerating AYVAKYT well1
Emily experiences reductions in spots, flushing and itching episodes, and improvement to her abdominal pain. She also reports the severity of her itching has reduced1
Please note that the patient quotes are illustrative and do not represent actual patient statements.
Anne
51-year-old female struggling with ongoing gastrointestinal issues, skin symptoms and fatigue
Fast fact
In PRISM, the largest European HCP/patient survey of SM burden to date, the most bothersome symptoms experienced by ISM patients were skin- and GI-related2
Patient history:
“For about two years, I’ve had ongoing diarrhoea that just wouldn’t go away – sometimes it even woke me up at night. I’d also get episodes of flushing for no clear reason.”
In the past year, Anne developed abdominal pain, nausea and vomiting, and constant fatigue
Her initial treatment included H2 antihistamines and proton pump inhibitors, which alleviated some of her symptoms but she felt they were not enough
Triggers:
Spicy foods
Citrus fruits
Stress
Precautionary measures:
Use of bowel incontinence products (for severe episodes)
After extensive testing by a gastroenterologist proved inconclusive for other causes, blood work revealed elevated tryptase, and Anne was referred to a haematologist. Diagnosis of indolent systemic mastocytosis was confirmed based on the presence of spindle-shaped mast cell aggregates (>25%) in bone marrow biopsy
Burden of ISM:
Despite Anne’s efforts to follow strict dietary rules, she often avoids social events out of fear of bowel incontinence accidents and is reluctant to discuss her condition.
“Dealing with gastrointestinal issues is a daily battle. Some days I use the bathroom multiple times before work, and constantly worry about finding a toilet when I’m out. It’s frustrating not having control over my own body…”
Treatment with AYVAKYT:
Anne begins taking AYVAKYT 25 mg orally, once daily in addition to her other medications (H2 antihistamines and proton pump inhibitors)1
At 24 weeks, she reports having experienced mild peripheral oedema, but it resolved without medical intervention or treatment interruption after one week, and generally she has been tolerating AYVAKYT well1
Anne reports improvement in her gastrointestinal symptoms, and reductions in flushing and fatigue. The episodes of diarrhoea, abdominal pain and nausea have lessened1
Please note that the patient quotes are illustrative and do not represent actual patient statements.
John
60-year-old male burdened by cognitive symptoms, bone pain and fatigue
Fast fact
In PRISM, the largest European HCP/patient survey of SM burden to date, between 9% and 42% of HCPs perceived that ISM impacts their patients ‘quite a bit’2*
Patient history:
“I’ve had these vague symptoms for as long as I can remember – headaches, feeling light-headed, brain fog, and being tired all the time.”
More recently, John has also developed chronic lower back pain
Triggers:
Stress
Heat
Precautionary measures:
Avoidance of symptom triggers and keeping a symptom diary
He was prescribed sodium cromolyn and a proton pump inhibitor, which provided relief from his symptoms but did not help with his back pain
John consulted an orthopaedist and underwent imaging examinations. After further re-evaluation, He was referred to a haematologist. Diagnosis of indolent systemic mastocytosis was confirmed based on a positive KIT D816V mutation and presence of spindle-shaped mast cell aggregates (>25%) in bone marrow biopsy
Burden of ISM:
John often cancels plans to spend time with his family due to his severe fatigue.
“I want to be there for my family, but some days I barely get out of bed as I feel exhausted before the day even begins. The bone pain is relentless, and the headache weighs me down like a heavy blanket. It is frustrating to feel my mind slipping too…”
Treatment with AYVAKYT:
John begins taking AYVAKYT 25 mg orally, once daily in addition to his other medications (sodium cromolyn and proton pump inhibitors)1
At 24 weeks, John reports that his brain fog lessened, and the episodes of headache, dizziness and fatigue have decreased. His lower back pain has also improved and he is tolerating AYVAKYT well1
*The reported values reflect the range observed across countries (Italy [n=201], Germany [n=122], UK [n=110], Austria [n=63], France [n=52], Switzerland [n=44] and Spain [n=19]). HCPs scored each statement on a 1–5 scale with the following items: A great deal; Quite a bit; Somewhat; A little bit; Not at all.2
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the product SmPC for how to report adverse reactions.1
References
AYVAKYT® (avapritinib). Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/ayvakyt-epar-product-information_en.pdf. Accessed June 2026.
Triggiani M, et al. Clin Exp Allergy. 2025;55(9):784–794.
The information on this website is intended for an international healthcare professional audience outside the United States and United Kingdom only
I confirm that I am a healthcare professional
I confirm that I am outside the US and UK
This website is intended for UK healthcare professionals only
I confirm that I am a healthcare professional
I confirm that I am in the UK
Our use of cookies
We use cookies to make our site work. We'd also like to set optional analytics cookies to help us improve it. We won't set optional cookies unless you enable them. Using this tool will set a cookie on your device to remember your preferences.
For more detailed information about the cookies we use, see our Cookie Policy.
Necessary cookies
Necessary cookies enable core functionality such as security, network management and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.
Analytics cookies
We'd like to set Google Analytics cookies to help us to improve our website by collecting and reporting information on how you use it. For more information on how these cookies work, please see our Cookie Policy. The cookies collect information in an anonymous form.
We use cookies that are strictly necessary to operate this website. We also use optional cookies to improve your accessibility to our website and its functionality, to analyse and track your use of our website, and to give you the best possible user experience. By clicking on the “Reject All Cookies" button, you understand that strictly necessary cookies will continue to be deployed for the operation of this website. For more detailed information on our use of cookies on this website, please read our Cookie Policy, which also explains how to customise your cookies settings. You can also “Accept All Cookies" or customise your cookies settings by clicking on the buttons provided below. Click “Cookie Settings” to update your personal cookie preferences or review our Privacy Policy.